These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25387217)

  • 41. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of glucagon secretion by incretins.
    Holst JJ; Christensen M; Lund A; de Heer J; Svendsen B; Kielgast U; Knop FK
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():89-94. PubMed ID: 21824261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anorexigenic effects of GLP-1 and its analogues.
    Gallwitz B
    Handb Exp Pharmacol; 2012; (209):185-207. PubMed ID: 22249815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects.
    Hartman I; Rojas E; Rodríguez-Molina D
    Am J Ther; 2013; 20(4):384-93. PubMed ID: 23459193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
    Vilsbøll T; Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():41-9. PubMed ID: 22405268
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
    Barrington P; Chien JY; Showalter HD; Schneck K; Cui S; Tibaldi F; Ellis B; Hardy TA
    Diabetes Obes Metab; 2011 May; 13(5):426-33. PubMed ID: 21251178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
    Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Development of the novel delivery system of GLP-1 administration for the treatment of diabetes mellitus].
    Nakazato M
    Nihon Rinsho; 2011 May; 69(5):918-22. PubMed ID: 21595282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.
    Montanya E
    Expert Opin Pharmacother; 2012 Jul; 13(10):1451-67. PubMed ID: 22725703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes.
    Setji T; Feinglos M
    Expert Rev Endocrinol Metab; 2013 May; 8(3):229-238. PubMed ID: 30780810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once-weekly albiglutide in the management of type 2 diabetes: patient considerations.
    Woodward HN; Anderson SL
    Patient Prefer Adherence; 2014; 8():789-803. PubMed ID: 24926194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists.
    Scheen AJ
    Lancet Diabetes Endocrinol; 2015 Sep; 3(9):667-9. PubMed ID: 26276241
    [No Abstract]   [Full Text] [Related]  

  • 54. GLP-1 Receptor Agonist as Adjuvant Therapy in Type 1 Diabetes: No Apparent Benefit for Beta-Cell Function or Glycemia.
    Redondo MJ; Bacha F
    J Clin Endocrinol Metab; 2020 Aug; 105(8):e3000-2. PubMed ID: 32485735
    [No Abstract]   [Full Text] [Related]  

  • 55. Generalized Edema Caused by Albiglutide: A Case Report.
    Aziz K; Shahbaz A; Zarghamravanbakhsh P; Ahmed SI; Sachmechi I
    Cureus; 2018 Jun; 10(6):e2801. PubMed ID: 30116680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular benefit of albiglutide.
    Lim GB
    Nat Rev Cardiol; 2018 Dec; 15(12):728. PubMed ID: 30310151
    [No Abstract]   [Full Text] [Related]  

  • 57. Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes.
    Fala L
    Am Health Drug Benefits; 2015 Mar; 8(Spec Feature):126-30. PubMed ID: 26629277
    [No Abstract]   [Full Text] [Related]  

  • 58. Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide.
    Koro C; Pientka J; Bainbridge V; O'Donnell N; Stender M; Stemhagen A
    Drugs Real World Outcomes; 2018 Mar; 5(1):55-67. PubMed ID: 29218595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study.
    Darpo B; Zhou M; Matthews J; Zhi H; Young MA; Perry C; Reinhardt RR
    Diabetes Ther; 2014 Dec; 5(2):609. PubMed ID: 25034668
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.